Todd Louis Rosenblat, MD

Specialties:
Cancer Care, Hematology, Internal Medicine, Medical Oncology

More specialties
Accepting New Patients

Profile Navigation

Overview
Schedule an Appointment
Location(s)
Insurance Accepted
Credentials & Experience
Research

Overview

Dr. Rosenblat is an assistant professor of medicine at Columbia University Medical Center, College of Physicians and Surgeons. He is a hematologist/oncologist with expertise in the diagnosis and treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome.
His research focuses on development of new and more effective treatments for patients with acute myeloid leukemia. This includes the development of novel drugs and drug combinations, as well as immunotherapy for myeloid leukemias. He received his MD degree from Stony Brook University and completed his fellowship in medical oncology/hematology at Memorial Sloan-Kettering Cancer Center.

Areas of Expertise / Conditions Treated

Acute Leukemia
Acute Lymphocytic Leukemia
Acute Myelogenous Leukemia
Aplastic Anemia
Chronic Leukemia
Chronic Lymphoid Leukemia
Chronic Myelogenous Leukemia
Essential Thrombocythemia
Hairy Cell Leukemia
Hematologic Malignancy
Large Granular Lymphocytic Leukemia
Leukemia
Lymphoblastic Leukemia
Myelodysplastic Syndrome
Myelofibrosis
Myeloproliferative Disease
Polycythemia Vera
Waldenstrom's Macroglobulinemia

Academic Appointments

Assistant Professor of Medicine at CUMC

Hospital Affiliations

NewYork-Presbyterian / Columbia University Irving Medical Center

Gender

Male

Schedule an Appointment

Phone Appointments

New and Existing Patients: (212) 305-5098

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.
Connect Sign In

Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue

New York, NY 10032



Phone: (212) 305-5098


Fax: (212) 305-8112



Open location in Google Maps

Insurance Accepted

AgeWell

Medicare Managed Care
Special Needs

Amida Care

Special Needs

Cigna

EPO
Great West (National)
HMO
POS
PPO

Emblem/GHI

Medicare Managed Care
PPO

Emblem/HIP

ConnectiCare
EPO
Essential Plan
HMO
Medicaid Managed Care
Medicare Managed Care
POS
PPO
Select Care (Exchange)
Vytra

Empire Blue Cross/Blue Shield

EPO
HMO
Medicare Managed Care
PPO

Empire Blue Cross Blue Shield HealthPlus

Child/Family Health Plus
Essential Plan
Medicaid Managed Care

Fidelis Care

Child/Family Health Plus
Essential Plan
Medicaid Managed Care
Medicare Managed Care

Healthfirst

Child/Family Health Plus
Leaf (Exchange)
Medicaid Managed Care
Medicare Managed Care

Local 1199

Local 1199

MagnaCare (National)

MagnaCare

Medicare

Railroad
Traditional Medicare

Multiplan

Multiplan

MVP Health Care

Child/Family Health Plus
Essential Plan
HMO
Medicaid Managed Care

Oxford Health Plans

Freedom
Liberty

RiverSpring

Special Needs

UnitedHealthcare

Compass (Exchange)
Empire Plan
HMO
Medicaid (Community Plan)
Medicare Managed Care
POS
PPO

VNSNY CHOICE

Medicare Managed Care
SelectHealth
Special Needs

WellCare

Medicaid Managed Care
Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

MD, State University of New York at Stony Brook, School of Medicine
2003 Stonybrook School of Medicine
Residency: NYU Medical Center
Fellowship: Memorial Sloan-Kettering Cancer Center

Board Certifications

Medical Oncology
Hematology
Internal Medicine

Research

Selected Publications

Renier J. Brentjens, Marco L. Davila, Isabelle Riviere, Jae Park, Xiuyan Wang, Lindsay G. Cowell, Shirley Bartido, Jolanta Stefanski, Clare Taylor, Malgorzata Olszewska, Oriana Borquez-Ojeda, Jinrong Qu, Teresa Wasielewska, Qing He, Yvette Bernal, Ivelise V. Rijo, Cyrus Hedvat, Rachel Kobos, Kevin Curran, Peter Steinherz, Joseph Jurcic, Todd Rosenblat, Peter Maslak, Mark Frattini and Michel Sadelain. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci Transl Med 2013: 177(5);177ra38
Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, Haidau A, Park JH, Ram SL, Orsini JM Jr, Sandhu S, Catchatourian R, Trifilio SM, Adel NG, Frankfurt O, Stein EM, Mallios G, Deblasio T, Jurcic JG, Nimer S, Peterson LC,Kwaan HC, Rowe JM, Douer D, Tallman MS. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013;37(9):1004-9
Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, O'Connell C, Solomon SR, Pigneux A, Vey N, Hills R, Jacobsen TF, Gianella-Borradori A, Foss O, Vetrhusand S, Giles FJ. International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2014 May 19


For a complete list of publications, please visit PubMed.gov